Sana Biotechnology (SANA) Expected to Announce Earnings on Wednesday

Sana Biotechnology (NASDAQ:SANA) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.51 on Monday. The company’s 50 day simple moving average is $3.36 and its 200 day simple moving average is $4.04. Sana Biotechnology has a 12 month low of $1.60 and a 12 month high of $6.55. The company has a market capitalization of $947.66 million, a P/E ratio of -3.62 and a beta of 2.17.

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC lifted its holdings in shares of Sana Biotechnology by 189.4% in the fourth quarter. Virtu Financial LLC now owns 119,312 shares of the company’s stock valued at $486,000 after purchasing an additional 78,088 shares in the last quarter. Invesco Ltd. raised its position in Sana Biotechnology by 24.1% during the fourth quarter. Invesco Ltd. now owns 561,835 shares of the company’s stock valued at $2,287,000 after buying an additional 109,078 shares during the period. XTX Topco Ltd raised its position in Sana Biotechnology by 9.9% during the fourth quarter. XTX Topco Ltd now owns 117,376 shares of the company’s stock valued at $478,000 after buying an additional 10,581 shares during the period. VARCOV Co. purchased a new stake in Sana Biotechnology in the 4th quarter worth about $264,000. Finally, Virtus Investment Advisers LLC boosted its position in Sana Biotechnology by 15.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 51,756 shares of the company’s stock worth $211,000 after acquiring an additional 6,958 shares during the period. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SANA. Wall Street Zen upgraded shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright reduced their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 4th. Morgan Stanley restated an “overweight” rating and issued a $12.00 target price on shares of Sana Biotechnology in a report on Friday, March 13th. Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings downgraded Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.20.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.